Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Crispr Therapeutics participates in a conference call with Morgan Stanley » 17:25
09/29/20
09/29
17:25
09/29/20
17:25
CRSP

Crispr Therapeutics

$84.98 /

+1.43 (+1.71%)

Australian Lead…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$84.98 /

+1.43 (+1.71%)

CRSP Crispr Therapeutics
$84.98 /

+1.43 (+1.71%)

09/22/20 Piper Sandler
Crispr Therapeutics remains a top pick at Piper Sandler
08/05/20 Citi
Citi reiterates Sell rating on Crispr Therapeutics with $31 price target
07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
CRSP Crispr Therapeutics
$84.98 /

+1.43 (+1.71%)

  • 01
    Jul
  • 21
    Nov
CRSP Crispr Therapeutics
$84.98 /

+1.43 (+1.71%)

Conference/Events
Ionis Pharmaceuticals management to meet virtually with Oppenheimer » 15:17
09/29/20
09/29
15:17
09/29/20
15:17
IONS

Ionis Pharmaceuticals

$48.46 /

-0.53 (-1.08%)

Virtual Meeting to be…

Virtual Meeting to be held on September 30 hosted by Oppenheimer.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$48.46 /

-0.53 (-1.08%)

IONS Ionis Pharmaceuticals
$48.46 /

-0.53 (-1.08%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
IONS Ionis Pharmaceuticals
$48.46 /

-0.53 (-1.08%)

IONS Ionis Pharmaceuticals
$48.46 /

-0.53 (-1.08%)

Initiation
Fly Intel: Top five analyst initiations » 09:54
09/29/20
09/29
09:54
09/29/20
09:54
PFE

Pfizer

$36.33 /

-0.08 (-0.22%)

, AXSM

Axsome Therapeutics

$71.88 /

-4.57 (-5.98%)

, SYY

Sysco

$61.95 /

+0.14 (+0.23%)

, USFD

US Foods

$22.88 /

-0.15 (-0.65%)

, LOB

Live Oak Bancshares

$25.50 /

+0.42 (+1.67%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) initiated with a Hold at Berenberg. 2. Axsome Therapeutics (AXSM) initiated with an Underperform at BofA. 3. Sysco (SYY) initiated with an Equal Weight at Morgan Stanley. 4. US Foods (USFD) initiated with an Equal Weight at Morgan Stanley. 5. Live Oak Bancshares (LOB) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
USFD US Foods
$22.88 /

-0.15 (-0.65%)

SYY Sysco
$61.95 /

+0.14 (+0.23%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

LOB Live Oak Bancshares
$25.50 /

+0.42 (+1.67%)

AXSM Axsome Therapeutics
$71.88 /

-4.57 (-5.98%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

05:28 Today Berenberg
Pfizer initiated with a Hold at Berenberg
09/21/20 Morgan Stanley
Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley
09/16/20 Baird
uniQure weakness a buying opportunity, says Baird
09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
AXSM Axsome Therapeutics
$71.88 /

-4.57 (-5.98%)

06:25 Today BofA
Axsome Therapeutics initiated with an Underperform at BofA
06:04 Today BofA
Axsome Therapeutics initiated with an Underperform at BofA
09/10/20 Morgan Stanley
Axsome Therapeutics initiated with an Overweight at Morgan Stanley
09/01/20 Guggenheim
Axsome's Alzheimer's agitation update better than expected, says Guggenheim
SYY Sysco
$61.95 /

+0.14 (+0.23%)

06:38 Today Morgan Stanley
Sysco initiated with an Equal Weight at Morgan Stanley
09/23/20 Wolfe Research
Sysco initiated with a Peer Perform at Wolfe Research
09/21/20 Credit Suisse
Sysco price target raised to $76 from $65 at Credit Suisse
09/10/20
Fly Intel: Top five analyst upgrades
USFD US Foods
$22.88 /

-0.15 (-0.65%)

06:41 Today Morgan Stanley
US Foods initiated with an Equal Weight at Morgan Stanley
09/22/20 Wolfe Research
US Foods initiated with an Outperform at Wolfe Research
09/17/20 BTIG
US Foods price target raised to $30 from $25 at BTIG
08/06/20 Credit Suisse
US Foods assumed with an Outperform at Credit Suisse
LOB Live Oak Bancshares
$25.50 /

+0.42 (+1.67%)

07:03 Today Raymond James
Live Oak Bancshares initiated with an Outperform at Raymond James
09/10/20 Truist
Live Oak Bancshares price target raised to $28 from $23 at Truist
09/09/20 Piper Sandler
Live Oak Bancshares assumed with a Neutral at Piper Sandler
05/12/20 Itau BBA
Live Oak Bancshares downgraded to Market Perform from Outperform at Itau BBA
USFD US Foods
$22.88 /

-0.15 (-0.65%)

SYY Sysco
$61.95 /

+0.14 (+0.23%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

AXSM Axsome Therapeutics
$71.88 /

-4.57 (-5.98%)

  • 19
    Dec
SYY Sysco
$61.95 /

+0.14 (+0.23%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

USFD US Foods
$22.88 /

-0.15 (-0.65%)

SYY Sysco
$61.95 /

+0.14 (+0.23%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

LOB Live Oak Bancshares
$25.50 /

+0.42 (+1.67%)

AXSM Axsome Therapeutics
$71.88 /

-4.57 (-5.98%)

USFD US Foods
$22.88 /

-0.15 (-0.65%)

SYY Sysco
$61.95 /

+0.14 (+0.23%)

PFE Pfizer
$36.33 /

-0.08 (-0.22%)

AXSM Axsome Therapeutics
$71.88 /

-4.57 (-5.98%)

Hot Stocks
Axsome Therapeutics announces $225M term loan facility with Hercules Capital » 07:14
09/29/20
09/29
07:14
09/29/20
07:14
AXSM

Axsome Therapeutics

$76.45 /

-0.51 (-0.66%)

, HTGC

Hercules Capital

$11.46 /

+0.18 (+1.60%)

Axsome Therapeutics…

Axsome Therapeutics (AXSM) has secured a $225M term loan facility with Hercules Capital (HTGC). The committed capital strengthens the Company's balance sheet through the anticipated commercial launches of its two lead product candidates, AXS-05 for major depressive disorder and AXS-07 for migraine, and extends its cash runway into at least 2024, based on current operating plans. Under the terms of the new $225M term loan facility, $60M may be drawn at closing; $115M may be drawn at the Company's option, in three separate tranches, upon approval of AXS-05 in MDD, upon approval of AXS-07 in migraine, and upon certain combined sales criteria for AXS-05 and AXS-07; and an additional $50M is available, subject to the approval of Hercules Capital, to support future strategic initiatives, including further pipeline advancement or expansion. Of the initial $60M, the Company drew down $50M at closing, with the additional $10M available to be drawn at the Company's option. A portion of the initial drawdown was used to repay the Company's previously existing $20M principal loan with Silicon Valley Bank along with associated final payment fees. The new term loan facility bears interest at a calculated prime-based variable rate currently at 9.15%. It matures in October 2025 and has an initial interest-only payment period of 30 months, which may be extended to up to 48 months upon the drawing of future tranches. Axsome will issue warrants to purchase 15,541 shares of Axsome common stock upon initial funding of the facility.

ShowHide Related Items >><<
HTGC Hercules Capital
$11.46 /

+0.18 (+1.60%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

06:25 Today BofA
Axsome Therapeutics initiated with an Underperform at BofA
06:04 Today BofA
Axsome Therapeutics initiated with an Underperform at BofA
09/10/20 Morgan Stanley
Axsome Therapeutics initiated with an Overweight at Morgan Stanley
09/01/20 Guggenheim
Axsome's Alzheimer's agitation update better than expected, says Guggenheim
HTGC Hercules Capital
$11.46 /

+0.18 (+1.60%)

07/31/20 Compass Point
Hercules upgraded to Buy on credit performance at Compass Point
07/31/20 Compass Point
Hercules Capital upgraded to Buy from Neutral at Compass Point
07/20/20 Piper Sandler
Hercules Capital assumed with an Overweight at Piper Sandler
06/19/20 Janney Montgomery Scott
Hercules Capital upgraded to Buy at Janney Montgomery Scott
HTGC Hercules Capital
$11.46 /

+0.18 (+1.60%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

  • 19
    Dec
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

Initiation
Axsome Therapeutics initiated with an Underperform at BofA » 06:25
09/29/20
09/29
06:25
09/29/20
06:25
AXSM

Axsome Therapeutics

$76.45 /

-0.51 (-0.66%)

BofA analyst Ashwani…

BofA analyst Ashwani Verma initiated coverage of Axsome Therapeutics with an Underperform rating and $66 price target. The analyst notes that his contrarian call is driven by expectations of disappointment from the company's 2021 primary care launches targeting depression and migraine because of their "undifferentiated" characteristics and "saturated" target markets. Verma adds that Alzheimer's Disease agitation is the biggest peak-sales opportunity for Axsome, but he points to multiple and viable competitor readouts beginning with Q4 of this year eroding the company's competitive position.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

06:04 Today BofA
Axsome Therapeutics initiated with an Underperform at BofA
09/10/20 Morgan Stanley
Axsome Therapeutics initiated with an Overweight at Morgan Stanley
09/01/20 Guggenheim
Axsome's Alzheimer's agitation update better than expected, says Guggenheim
07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

  • 19
    Dec
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

Initiation
Axsome Therapeutics initiated with an Underperform at BofA » 06:04
09/29/20
09/29
06:04
09/29/20
06:04
AXSM

Axsome Therapeutics

$76.45 /

-0.51 (-0.66%)

BofA initiated coverage…

BofA initiated coverage of Axsome Therapeutics with an Underperform rating and $66 price target.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

09/10/20 Morgan Stanley
Axsome Therapeutics initiated with an Overweight at Morgan Stanley
09/01/20 Guggenheim
Axsome's Alzheimer's agitation update better than expected, says Guggenheim
07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

  • 19
    Dec
AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

AXSM Axsome Therapeutics
$76.45 /

-0.51 (-0.66%)

Hot Stocks
Celyad, Merck enter collaboration to evaluate CYAD-101 with Keytruda » 05:14
09/29/20
09/29
05:14
09/29/20
05:14
CYAD

Celyad

$9.16 /

+ (+0.00%)

, MRK

Merck

$82.80 /

-0.15 (-0.18%)

Celyad (CYAD) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$82.80 /

-0.15 (-0.18%)

CYAD Celyad
$9.16 /

+ (+0.00%)

CYAD Celyad
$9.16 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
MRK Merck
$82.80 /

-0.15 (-0.18%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

Conference/Events
Crispr Therapeutics participates in a conference call with Morgan Stanley » 04:55
09/29/20
09/29
04:55
09/29/20
04:55
CRSP

Crispr Therapeutics

$83.60 /

-0.45 (-0.54%)

Australian Lead…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$83.60 /

-0.45 (-0.54%)

CRSP Crispr Therapeutics
$83.60 /

-0.45 (-0.54%)

09/22/20 Piper Sandler
Crispr Therapeutics remains a top pick at Piper Sandler
08/05/20 Citi
Citi reiterates Sell rating on Crispr Therapeutics with $31 price target
07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
CRSP Crispr Therapeutics
$83.60 /

-0.45 (-0.54%)

  • 01
    Jul
  • 21
    Nov
CRSP Crispr Therapeutics
$83.60 /

-0.45 (-0.54%)

Yesterday
On The Fly
Fly Intel: After-Hours Movers » 18:27
09/28/20
09/28
18:27
09/28/20
18:27
FLUX

Flux Power

$5.45 /

+0.05 (+0.93%)

, RLGT

Radiant Logistics

$5.23 /

+0.16 (+3.16%)

, DNLI

Denali Therapeutics

$35.27 /

+0.14 (+0.40%)

, DYN

Dyne Therapeutics

$21.49 /

-0.52 (-2.36%)

, SNOW

Snowflake

$250.29 /

+21.06 (+9.19%)

, UNFI

United Natural Foods

$19.13 /

+1.235 (+6.90%)

, BEAM

Beam Therapeutics

$26.87 /

+0.14 (+0.52%)

Check out this evening's…

ShowHide Related Items >><<
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

05/12/20 Lake Street
Radiant Logistics price target lowered to $7 from $9 at Lake Street
02/28/20 Benchmark
Radiant Logistics initiated with a Buy at Benchmark
DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

09/14/20 JPMorgan
Denali Therapeutics resumed with an Overweight at JPMorgan
08/20/20 H.C. Wainwright
Denali Therapeutics price target raised to $45 from $28 at H.C. Wainwright
08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20
Snowflake initiated with a Sell at Summit Insights
09/21/20 Summit Insights
Snowflake initiated with a Sell at Summit Insights
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

09/23/20 Northcoast
United Natural Foods upgraded to Buy from Neutral at Northcoast
07/30/20 MKM Partners
United Natural Foods initiated with a Buy at MKM Partners
07/29/20 MKM Partners
United Natural Foods initiated with a Buy at MKM Partners
07/16/20 BTIG
United Natural Foods initiated with a Neutral at BTIG
BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 William Blair
Beam Therapeutics initiated with an Outperform at William Blair
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

  • 01
    Oct
  • 17
    Sep
  • 16
    Sep
  • 29
    Jan
  • 06
    Feb
SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

Syndicate
Beam Therapeutics announces offering of 4.5M shares of common stock » 16:19
09/28/20
09/28
16:19
09/28/20
16:19
BEAM

Beam Therapeutics

$26.87 /

+0.14 (+0.52%)

Beam Therapeutics…

Beam Therapeutics announced the commencement of a proposed public offering of 4.5M shares of its common stock. J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.

ShowHide Related Items >><<
BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 William Blair
Beam Therapeutics initiated with an Outperform at William Blair
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

  • 06
    Feb
BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.